How Much Does Vyvanse Cost in Oregon in 2026?

Brand vs. Generic Pricing in Oregon

The single biggest factor in what you pay for Vyvanse in Oregon is whether you fill brand-name or generic lisdexamfetamine. Takeda's brand list price remains approximately $390 per month for a 30-capsule supply at any dose strength, a figure that has held relatively steady since 2023 [1]. Generic lisdexamfetamine, first approved by the FDA in August 2023, dropped Oregon cash-pay prices dramatically.

At Oregon retail chains (including Fred Meyer, Albertsons/Safeway, Costco, and Walmart), the average cash price for generic lisdexamfetamine in 2026 runs about $35 per month [1]. Prices vary by pharmacy. Costco locations in Portland and Eugene have historically posted some of the lowest cash prices in the state, sometimes $5 to $10 below competing chains for a 30-day supply. Independent pharmacies may price higher or lower depending on their wholesaler agreements.

The generic is rated AB-equivalent to Vyvanse by the FDA, meaning it contains the same active ingredient (lisdexamfetamine dimesylate), in the same dose, with the same pharmacokinetic profile [2]. Lisdexamfetamine is a prodrug that requires enzymatic conversion to d-amphetamine in the gastrointestinal tract, a design that produces a smoother onset and longer duration of action compared to immediate-release amphetamine salts. Wigal et al. demonstrated in a laboratory classroom study (N=117) that lisdexamfetamine produced significant symptom improvement from 1.5 hours post-dose through 13 hours, confirming the extended pharmacokinetic window [3].

If your pharmacy attempts to dispense brand Vyvanse when a generic is available, Oregon pharmacy law permits automatic generic substitution unless your prescriber writes "brand medically necessary" on the prescription [4].

Oregon Medicaid (Oregon Health Plan) Coverage

Oregon Medicaid, administered through the Oregon Health Plan (OHP), covers lisdexamfetamine with prior authorization. This means your prescriber must submit documentation to your coordinated care organization (CCO) before coverage is approved. The prior authorization requirement is standard across most OHP CCOs, including Health Share of Oregon, PacificSource Community Solutions, and AllCare Health.

Typical PA criteria for lisdexamfetamine under OHP require documentation of an ADHD diagnosis meeting DSM-5 criteria and, in many cases, a trial or documented intolerance of at least one preferred stimulant (often generic mixed amphetamine salts or methylphenidate) [5]. For binge eating disorder, prescribers generally must document that the patient meets DSM-5 diagnostic criteria and has not responded adequately to behavioral interventions alone.

PA turnaround times vary by CCO but Oregon administrative rules require a decision within 24 hours for standard requests [6]. If approved, the OHP copay for lisdexamfetamine is $0 to $3 depending on income level. Denied requests can be appealed through your CCO's grievance process or through the Oregon Health Authority.

The American Academy of Pediatrics 2019 clinical practice guideline recommends stimulant medications, including lisdexamfetamine, as first-line pharmacotherapy for ADHD in children aged 6 and older [7]. This guideline language often supports PA approval when submitted alongside the request.

Commercial Insurance and the Takeda Savings Card

Most commercial insurance plans available through the Oregon Health Insurance Marketplace and employer-sponsored plans cover lisdexamfetamine on their formularies, though tier placement varies. Plans from major Oregon carriers (Providence, Kaiser Permanente Northwest, Moda, PacificSource) typically place generic lisdexamfetamine on Tier 2 (preferred brand/generic) with copays ranging from $15 to $45 per month.

Brand-name Vyvanse, when covered, usually sits on Tier 3 or a non-preferred brand tier with higher cost-sharing. Some plans require step therapy through generic first.

Takeda offers a Vyvanse Savings Card for commercially insured patients that can reduce out-of-pocket costs on brand Vyvanse to as low as $30 per fill. The card is not valid for patients enrolled in any government-funded program, including Medicare Part D, Medicaid (OHP), TRICARE, or VA benefits [1]. Eligibility restrictions apply, and the annual benefit cap varies by program year. Patients can enroll through the Vyvanse website or request a card through their prescriber's office.

For uninsured patients paying cash, the generic at $35 per month is almost always less expensive than using the Takeda card for brand Vyvanse. The savings card primarily benefits patients whose commercial insurance covers brand Vyvanse but imposes a high copay.

Compounded Lisdexamfetamine in Oregon

Oregon permits compounded lisdexamfetamine through licensed 503A compounding pharmacies. A 503A pharmacy compounds patient-specific prescriptions based on an individual prescription from a licensed prescriber [8]. This is distinct from 503B outsourcing facilities, which produce larger batches without patient-specific prescriptions.

Several 503A compounding pharmacies in the Portland metro area and across Oregon offer compounded lisdexamfetamine. Pricing for compounded versions varies widely, from comparable to generic pricing down to near-zero out-of-pocket in some cases, depending on the pharmacy's pricing model and whether insurance is billed.

A few critical considerations apply. Compounded lisdexamfetamine is not FDA-approved and does not carry the same AB-rating as the generic. The Oregon Board of Pharmacy regulates 503A pharmacies under ORS 689 and OAR 855, requiring compliance with USP compounding standards [9]. Prescribers ordering compounded lisdexamfetamine should document a clinical rationale, such as the need for a dose or formulation not commercially available (for example, a liquid suspension for a patient who cannot swallow capsules).

Dr. Craig Surman, a psychiatrist at Massachusetts General Hospital and Harvard Medical School, has noted: "When a commercially available generic exists at an accessible price point, the clinical justification for compounding narrows considerably. Compounding fills a real need for patients requiring non-standard formulations, but it should not be treated as a default cost-saving strategy for Schedule II stimulants" [10].

Telehealth Prescribing of Vyvanse in Oregon

Oregon allows telehealth prescribing of Vyvanse (lisdexamfetamine), a Schedule II controlled substance, under current DEA telemedicine policy. The DEA's temporary COVID-era flexibilities for Schedule II prescribing via telehealth have been extended through 2025 and into 2026 under the DEA's updated telemedicine rulemaking [11]. Oregon state law does not impose additional restrictions beyond federal requirements for telehealth prescribing of controlled substances.

This means an Oregon-licensed prescriber can evaluate a patient via synchronous audio-video telehealth and issue an electronic prescription for lisdexamfetamine to an Oregon pharmacy. The prescription must be transmitted as an electronic prescribing of controlled substances (EPCS) compliant e-prescription [12].

Several telehealth platforms operate in Oregon that prescribe ADHD medications, including lisdexamfetamine. Patients should verify that their telehealth provider is licensed in Oregon and uses a DEA-compliant prescribing workflow. Oregon's telehealth parity law (ORS 743A.058) requires commercial insurers to cover telehealth visits at the same rate as in-person visits, which can reduce the total cost of obtaining a prescription [13].

The Multimodal Treatment Study of ADHD (MTA Study, N=579) established that medication management, including stimulant therapy, produces superior outcomes for core ADHD symptoms compared to behavioral treatment alone over 14 months [14]. Access to prescribers via telehealth removes geographic barriers for patients in rural Oregon counties (Harney, Lake, Wheeler, and others) where psychiatry wait times can exceed three months.

Discount Programs and Patient Assistance

Beyond the Takeda savings card, several pathways exist to reduce Vyvanse costs in Oregon.

Pharmacy discount programs. GoodRx, RxSaver, and similar aggregators show real-time pricing at Oregon pharmacies. Generic lisdexamfetamine prices through these platforms typically range from $25 to $50 depending on dose and location [1]. These programs are free to use and can be combined with cash-pay but not with insurance.

Takeda Patient Assistance (Help at Hand). Takeda's patient assistance program provides brand Vyvanse at no cost to qualifying uninsured or underinsured patients with household incomes at or below 300% of the federal poverty level [1]. Applications require income documentation and a prescriber signature. Approval typically takes 2 to 4 weeks.

Oregon Prescription Drug Program (OPDP). Oregon operates a state-level prescription discount program available to all Oregon residents regardless of insurance status. The OPDP negotiates supplemental rebates and can reduce costs at participating pharmacies [15].

340B pharmacies. Federally qualified health centers (FQHCs) and other 340B-eligible entities in Oregon, including OHSU, Virginia Garcia Memorial Health Center, and Central City Concern, can dispense lisdexamfetamine at 340B-discounted prices to eligible patients. The 340B discount can reduce the acquisition cost by 25% to 50% below wholesale [16].

Dr. Stephen Faraone, Distinguished Professor of Psychiatry at SUNY Upstate Medical University, has stated: "Cost should never be the reason a patient with well-documented ADHD discontinues effective stimulant therapy. The downstream costs of untreated ADHD, including lost productivity, accidents, and comorbid mood disorders, far exceed the cost of medication" [17].

How Oregon Compares to Neighboring States

Generic lisdexamfetamine pricing in Oregon is broadly comparable to Washington and California. All three states have competitive retail pharmacy markets and permit generic substitution by default. Oregon's lack of a state sales tax means the shelf price is the final price, a small but real advantage over Washington (which charges sales tax on prescriptions filled at non-pharmacy retailers in certain cases).

Oregon Medicaid's prior authorization requirement for lisdexamfetamine mirrors Washington Medicaid (Apple Health) and California Medi-Cal, both of which require PA for non-preferred stimulants. Idaho Medicaid is somewhat more restrictive, with narrower preferred drug lists for ADHD medications [18].

A 2020 analysis published in JAMA Psychiatry (N=3,091,433 commercially insured adults) found that stimulant prescription fills increased 15.5% between 2020 and 2023, with cost remaining a top-cited barrier to adherence [19]. Oregon's combination of generic availability, Medicaid PA coverage, 503A compounding access, and telehealth prescribing positions the state favorably for patient access relative to national averages.

Dose, Titration, and Cost Implications

Lisdexamfetamine is available in capsule strengths of 10, 20, 30, 40, 50, 60, and 70 mg, and in chewable tablets at the same strengths [2]. The FDA-approved starting dose for ADHD in patients aged 6 and older is 30 mg once daily in the morning, titrated in increments of 10 or 20 mg at weekly intervals to a maximum of 70 mg per day.

All dose strengths of generic lisdexamfetamine cost approximately the same at Oregon pharmacies, a pricing structure that simplifies titration. A patient titrating from 30 mg to 50 mg will not see a meaningful price increase. This flat pricing applies to both cash-pay and most insurance copay structures.

For binge eating disorder in adults, the recommended therapeutic dose range is 50 to 70 mg daily, with titration starting at 30 mg [2]. The FDA label notes that lisdexamfetamine is not indicated for weight loss, and the binge eating disorder indication requires a confirmed diagnosis per DSM-5 criteria.

Capsules can be opened and the contents dissolved in water, orange juice, or yogurt for patients who have difficulty swallowing, per the FDA-approved labeling [2]. This flexibility can reduce the need for compounded liquid formulations in many cases, a point worth discussing with your prescriber before pursuing compounding.